Lyve-1 Rat anti-Mouse, eFluor 660, Clone: ALY7, eBioscience™

Rat Monoclonal Antibody

Overview
Brand: Affymetrix eBioscience

Manufacturer Part Number: 50-0443-82

100UG ANTI-MOUSE LYVE-1 EFLUOR® 660

UNSPSC: 12352200

Code: Z2

Additional Details:
Additional Details: Weight: 0.25000kg



Disclaimers: For Research Use Only.

Product Code. 15321870

Quantity Price
1 £ 226.0 / 100µg
Estimated Shipment date
from Supplier 08-12-2016
Add to basket


Description and Specification

Specification

Antigen Lyve-1
Applications Flow Cytometry
Applications Immunohistochemistry (Frozen)
Clone ALY7
Concentration 0.2mg/mL
Conjugate eFluor 660
Format Conjugated
Formulation aqueous buffer, 0.09% sodium azide, may contain carrier protein/stabilizer
Gene Alias Lymphatic Vessel Endothelial Hyaluronan Receptor 1
Host Species Rat
Isotype IgG1
Quantity 100μg
Regulatory Status RUO
Species Reactivity Mouse
Storage Requirements Store at 2-8°C. Do not freeze. Light-sensitive material.
Primary or Secondary Primary
Monoclonal or Polyclonal Monoclonal

The monoclonal antibody ALY7 recognizes mouse LYVE-1, a transmembrane glycoprotein with similarity to CD44. The extracellular domain contains a conserved hyaluronan binding domain also found in CD44. Expression is found on lymphatic and liver endothelial cells and some populations of macrophages. The lymphatic system is responsible for transporting proteins and cells (especially dendritic cells) to tissues throughout the body, thereby acting as immune surveyors. LYVE-1 is one characteristic protein, along with podoplanin, PROX-1, Tie-2 and VEGFR-3, that is expressed on lymphatic endothelial cells (LECS). The ligand for LYVE-1 is hyaluronan, a large mucopolysaccharide. Although LYVE-1 can bind hyaluronan in vitro, the site for ligand binding in vivo is masked by sialyated O-linked glycan chains. It is postulated that binding to ligand requires modification/unmasking to expose the binding site. The development and remodeling of the endothelium after injury is an area of extensive study. When transplanted, hematopoietic stem cells (HSCs) can give rise to LECs that integrate into the endothelium in normal and metastatic tissue.